NASDAQ · PHVS
Healthcare · Biotechnology
$37.74
Up+$0.46 (+1.23%)
Updated Sep 10, 2026, 4:59 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PHVS closed at $37.74 after 20 trading sessions, up 3.51% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $38.26 | $39.18 | $37.05 | $37.74 | 1.43M |
| Sep 8, 2026 | $40.96 | $43.25 | $37.60 | $37.84 | 6.33M |
| Sep 4, 2026 | $35.36 | $36.39 | $35.21 | $35.25 | 483.98K |
| Sep 3, 2026 | $35.39 | $35.88 | $34.575 | $35.66 | 357.06K |
| Sep 2, 2026 | $35.05 | $35.97 | $34.04 | $35.17 | 320.88K |
| Sep 1, 2026 | $34.45 | $35.07 | $33.80 | $34.93 | 394.44K |
| Aug 31, 2026 | $35.31 | $35.7275 | $34.13 | $34.61 | 557.52K |
| Aug 28, 2026 | $37.00 | $37.405 | $35.26 | $35.32 | 479.03K |
| Aug 27, 2026 | $37.00 | $37.4899 | $36.2988 | $37.00 | 765.05K |
| Aug 26, 2026 | $37.31 | $37.40 | $36.24 | $37.00 | 448.94K |
| Aug 25, 2026 | $37.32 | $38.00 | $36.69 | $37.23 | 861.18K |
| Aug 24, 2026 | $36.27 | $38.13 | $35.70 | $37.31 | 691.82K |
| Aug 21, 2026 | $36.61 | $36.9325 | $36.12 | $36.27 | 515.46K |
| Aug 20, 2026 | $36.13 | $36.82 | $35.45 | $36.39 | 627.8K |
| Aug 19, 2026 | $36.80 | $36.883 | $35.535 | $36.27 | 1.04M |
| Aug 18, 2026 | $35.35 | $36.6539 | $35.08 | $36.10 | 609.43K |
| Aug 17, 2026 | $34.71 | $35.61 | $34.71 | $35.32 | 556.78K |
| Aug 14, 2026 | $34.00 | $36.18 | $33.54 | $35.14 | 862.9K |
| Aug 13, 2026 | $36.50 | $36.93 | $33.79 | $34.04 | 738.22K |
| Aug 12, 2026 | $34.03 | $36.645 | $33.00 | $36.46 | 1.27M |
The latest Smart Investors Daily articles mentioning PHVS.
PHVS research
Company profile and research snapshot.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Sep 9, 2026 | Morgan Stanley | Overweight | — |
| Sep 9, 2026 | Wells Fargo | Overweight | — |
| Sep 9, 2026 | Citizens | Market Outperform | — |
| Sep 9, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 8, 2026
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema September...
Benzinga · Sep 8, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Pharvaris (NASDAQ:PHVS) with a Buy and maintains $60 price target.
Benzinga · Sep 8, 2026
Pharvaris (PHVS) stock surges 17% on positive Phase 3 HAE trial data. Deucrictibant XR reduced monthly attacks up to 87%.
Benzinga · Sep 8, 2026
Wedbush analyst Laura Chico reiterates Pharvaris (NASDAQ:PHVS) with a Outperform and maintains $42 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PHVS.
